Sonoma Pharmaceuticals (SNOA) Gross Margin (2010 - 2026)

Sonoma Pharmaceuticals' Gross Margin history runs 17 years deep, the most recent figure standing at 39.22% for Q1 2026.

• On a quarterly basis, Gross Margin fell 148.0% year-over-year to 39.22% in Q1 2026; TTM through Mar 2026 was 37.97%, a 28.0% decrease from a year earlier, with the FY2026 full-year figure at 37.97%, down 28.0% from the prior year.
• Gross Margin improved to 39.22% in Q1 2026 per SNOA's latest filing, from 37.94% in the prior quarter.
• Across five years, Gross Margin topped out at 46.53% in Q4 2023 and bottomed at 4.18% in Q1 2022.
• The 5-year median for Gross Margin is 37.83% (2025), against an average of 35.44%.
• Across the five-year window, Gross Margin plunged 1323 bps in 2022 and jumped 2449 bps in 2023, its largest moves.
• Year by year, Gross Margin stood at 28.23% in 2022, then soared by 65 bps to 46.53% in 2023, then retreated by 23 bps to 35.63% in 2024, then rose by 6 bps to 37.94% in 2025, then advanced by 3 bps to 39.22% in 2026.
• Per Business Quant, the three latest SNOA Gross Margin figures stand at 39.22% (Q1 2026), 37.94% (Q4 2025), and 37.83% (Q3 2025).